IQ-AI Regulatory News (IQAI)

Flying Brands PLC

("Flying Brands" or the "Company")

IB Software Chosen by St. Savvas Anti-Cancer and Oncology Hospital

Solution will be used to image brain tumours and assess treatment response

Imaging Biometrics®, LLC ("IB"), a subsidiary of Flying Brands Limited (LON:FBDU), announced today that the General Anti-Cancer and Oncological Hospital of Athens "St. Savvas", Athens, Greece has installed its full suite of IB Software to help assess treatment response for patients with brain tumours.

Amongst the IB software to be used will be IB Rad Tech. IB Rad Tech is a software engine that leverages the core processing libraries of other IB products and further streamlines the workflow. For example, the approach used to generate IB's standardised fractional tumor burden (sFTB) maps relies on the robust perfusion magnetic resonance imaging (p-MRI) available in IB Neuro, and a patented image intensity "standardisation" algorithm incorporated in IB Delta Suite. Exclusive to IB, standardisation enables quantitative and automated inter- and intra-study comparison, resulting in the application of precision/personalised medicine.

Dr. Vasileios Κ. Katsaros MD, PhD, Head of the Department of MRI and Neuroradiology, in General Anti-Cancer and Oncological Hospital of Athens "St. Savvas", Clinical and Research Associate, Department of Neurosurgery, University of Athens, General Hospital of Athens "Evangelismos" and Clinical and Research Affiliate, Department of Neuroradiology, University College of London (UCL), as well as co-founder of the Hellenic Neuro-Oncology Group (HENOG) said, "The sooner you can assess if a brain tumour patient is responding to a given therapy, the better the outcome for the patient. IB's tools provide additional information which quantifies the true tumour burden in a repeatable and streamlined manner. This information has the potential to impact the best clinical practice concerning treatment management decisions and could also be used as a discussion aide with patients."

Dr. Katsaros added, "It is critical to know if a change in an imaging biomarker accurately represents a change in tumour growth or response to treatment. Without it, surgeons, radiotherapists and oncologists may require more tests or require more time to follow-up the patients and to know, with confidence, that a treatment protocol is effective."

ABOUT General Anti-Cancer and Oncological Hospital of Athens "St. Savvas"

Founded in 1935, the Greek Cancer Institute is a tertiary public hospital in the service for oncological patients from all over the Greece. From 1940s, there were four oncological departments, five out-patient clinics and four scientific laboratories. In 1945 (after the end of World-War II), the hospital began again to operate under normal conditions with the addition, to the already two existing, of one more Radiotherapy department, while the Microbiological and Radiology Department were modernised, a trend that is followed for more than 70 years and on, including advanced methods for diagnosis and treatment.

ABOUT Imaging Biometrics™, LLC

Imaging Biometrics, a subsidiary of Flying Brands Limited (LON:FBDU), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

-Ends-